Publicaciones en colaboración con investigadores/as de University Hospital of Lausanne (18)

2024

  1. Evolution and advancements in genomics and epigenomics in OA research: How far we have come

    Osteoarthritis and Cartilage

  2. SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

    Annals of Oncology, Vol. 35, Núm. 1, pp. 66-76

2023

  1. Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges

    Nature Reviews Clinical Oncology, Vol. 20, Núm. 10, pp. 664-677

  2. Three decades of advancements in osteoarthritis research: insights from transcriptomic, proteomic, and metabolomic studies

    Osteoarthritis and Cartilage

2022

  1. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial

    Annals of Oncology, Vol. 33, Núm. 2, pp. 181-192

2021

  1. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  2. Multicenter evaluation of rapid BACpro® II for the accurate identification of microorganisms directly from blood cultures using MALDI-TOF MS

    Diagnostics, Vol. 11, Núm. 12

2020

  1. A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial

    Annals of Oncology, Vol. 31, Núm. 12, pp. 1734-1745

  2. Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment

    Lung Cancer, Vol. 150, pp. 90-96

  3. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial

    The Lancet Oncology, Vol. 21, Núm. 5, pp. 645-654

2019

  1. Genetic Mosaicism in Calmodulinopathy

    Circulation: Genomic and Precision Medicine, Vol. 12, Núm. 9, pp. 375-385

  2. Maternal and fetal genetic effects on birth weight and their relevance to cardio-metabolic risk factors

    Nature Genetics, Vol. 51, Núm. 5, pp. 804-814

2016

  1. Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

    Autophagy

  2. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

    Autophagy, Vol. 12, Núm. 1, pp. 1-222

  3. Liver Retransplantation in Patients with HIV-1 Infection: An International Multicenter Cohort Study

    American Journal of Transplantation, Vol. 16, Núm. 2, pp. 679-687

2015

  1. Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey

    Clinical Microbiology and Infection, Vol. 21, Núm. 6, pp. 604.e1-604.e9

  2. Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study

    PLoS Medicine, Vol. 12, Núm. 3

2009

  1. Comparable survival between HIV+ and HIV- non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation

    Blood, Vol. 113, Núm. 23, pp. 6011-6014